Anger and aggressive behavior (AB) are two of the main post-stroke behavioral manifestations, which could imply both an anger trait (TA) or a state condition of anger (SA). Serotonergic system is thought to play an inhibitory control on aggressive impulse. Nevertheless, whether 5HT has the same role in TA and in SA, is still debated. Intensity dependence of auditory evoked potentials (IDAP) is thought to be inversely related to the central 5HT tone. The aim of this study was to evaluate, in acute stroke patients, the 5HT system involvement in AB by IDAP. Consecutive stroke patients were evaluated and compared with healthy controls. The Spielberger Trait Anger Scale (STAS) was used to assess AB, SA and TA. Patients with AB and TA showed a significantly increased IDAP value, whereas patients with SA had a significantly lower IDAP; this indicates an increased 5HT tone. In acute stroke patients with AB, there is a decreased central 5HT tone. Surprisingly, we found an opposite 5HT feature between patients with TA and those showing SA, suggesting that the hypothesis of aggression based on 5HT deficiency requires further investigations. This might open new strategies in the treatment of post-stroke AB.

Keywords:
Anger and aggressive behavior, Evoked potentials, Intensity dependence of auditory-evoked potentials, Stroke
1.
Santos CO, Caeiro L, Ferro JM, Albuquerque R, Luisa Figueira M: Anger, hostility and aggression in the first days of acute stroke. Eur J Neurol 2006;13:351-358.
2.
Kim JS, Choi S, Kwon SU, Seo YS: Inability to control anger or aggression after stroke. Neurology 2002;58:1106-1108.
3.
Aybek S, Carota A, Ghika-Schmid F, Berney A, Melle GV, Guex P, Bogousslavsky J: Emotional behavior in acute stroke: the lausanne emotion in stroke study. Cogn Behav Neurol 2005;18:37-44.
4.
Williams JE, Nieto FJ, Sanford CP, Couper DJ, Tyroler HA: The association between trait anger and incident stroke risk: the atherosclerosis risk in communities (ARIC) study. Stroke 2002;33:13-19.
5.
Ghika-Schmid F, van Melle G, Guex P, Bogousslavsky J: Subjective experience and behavior in acute stroke: the lausanne emotion in acute stroke study. Neurology 1999;52:22-28.
6.
Friedman HS: Understanding hostility, coping, and health; in Friedman HS (ed): Hostility, Coping & Health. Washington DC, American Psychological Association, 1992.
7.
Cummings JL, Bogousslavsky J: Emotional consequences of focal brain lesions: an overview; in Bogousslavsky J, Cummings JL (eds): Behavior and Mood Disorders in Focal Brain Lesions. Cambridge, Cambridge University Press, 2000, pp 1-20.
8.
Giacalone E, Tansella M, Valzelli L, Garattini S: Brain serotonin metabolism in isolated aggressive mice. Biochem Pharmacol 1968;17:1315-1327.
9.
Brown G, Goodwin F, Ballenger J, Goyer P, Major L: Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychiatry Res 1979;1:131-139.
10.
Brown G, Ebert M, Goyer P, Jimerson D, Klein W, Bunney W, Goodwin F: Aggression, suicide, and serotonin: relationships to CSF amine metabolites. Am J Psychiatry 1982;139:741-746.
11.
Linnoila M, Virkkunen M, Scheinin M, Nuutila A, Rimon R, Goodwin F: Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sci 1983;33:2609-2614.
12.
de Boer SF, Koolhaas JM: 5-ht1a and 5-ht1b receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis. Eur J Pharmacol 2005;526:125-139.
13.
Coccaro EF: Central serotonin and impulsive aggression. Br J Psychiatry Suppl 1989;8:52-62.
14.
van der Vegt BJ, Lieuwes N, Cremers TI, de Boer SF, Koolhaas JM: Cerebrospinal fluid monoamine and metabolite concentrations and aggression in rats. Horm Behav 2003;44:199-208.
15.
Hegerl U, Juckel G: Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: a new hypothesis. Biol Psychiatry 1993;33:173-187.
16.
Juckel G, Hegerl U, Molnar M, Csepe V, Karmos G: Auditory evoked potentials reflect serotonergic neuronal activity - a study in behaving cats administered drugs acting on 5-HT1A autoreceptors in the dorsal raphe nucleus. Neuropsychopharmacology 1999;21:710-716.
17.
von Knorring L, Johansson F: Changes in the augmenter-reducer tendency and in pain measures as a result of treatment with a serotonin-reuptake inhibitor-zimelidine. Neuropsychobiology 1980;6:313-318.
18.
Strobel A, Debener S, Schmidt D, Hünnerkopf R, Lesch KP, Brocke B: Allelic variation in serotonin transporter function associated with the intensity dependence of the auditory evoked potential. Am J Med Genet B Neuropsychiatr Genet 2003;118:41-47.
19.
Park YM, Lee SH, Lee HJ, Kang SG, Min JA, Chae JH: Association between BDNF gene polymorphisms and serotonergic activity using loudness dependence of auditory evoked potentials in healthy subjects. PLoS One 2013;8:e60340.
20.
Wang W, Timsit-Berthier M, Schoenen J: Intensity dependence of auditory evoked potentials is pronounced in migraine: an indication of cortical potentiation and low serotonergic neurotransmission? Neurology 1996;46:1404-1409.
21.
Proietti-Cecchini A, Afra J, Schoenen J: Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of CNS serotonin transmission in man: demonstration of a central effect for the 5HT agonist zolmitriptan (311c90, zomig). Cephalalgia 1997;17:849-854.
22.
Linka T, Müller BW, Bender S, Sartory G: The intensity dependence of the auditory evoked n1 component as a predictor of response to citalopram treatment in patients with major depression. Neurosci Lett 2004;367:375-378.
23.
Gallinat J, Bottlender R, Juckel G, Munke-Puchner A, Stotz G, Kuss HJ, Mavrogiorgou P, Hegerl U: The loudness dependency of the auditory evoked n1/p2-component as a predictor of the acute SSRI response in depression. Psychopharmacology (Berl) 2000;148:404-411.
24.
Park YM, Lee SH: Clinical usefulness of loudness dependence of auditory evoked potentials (LDAEP) in patients with bipolar disorder. Psychiatry Investig 2013;10:233-237.
25.
Rocco A, Afra J, Toscano M, Sirimarco G, Di Clemente L, Altieri M, Lenzi GL, Di Piero V: Acute subcortical stroke and early serotonergic modification: a IDAP study. Eur J Neurol 2007;14:1378-1382.
26.
Jorm J, Jacomb P: The informant questionnaire on cognitive decline in the elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med 1989;19:1015-1022.
27.
Spielberger C, Jacobs G, Russell S, Crane R: Assessment of anger: the state-trait anger-scale; in Butcher J, Spielberger C (eds): Advances in personality assessment. Hillsdale, Lawrence Erlbaum Associates, 1983, vol 2, pp 161-189.
28.
Williams JE, Paton CC, Siegler IC, Figenbrodt ML, Nieto FJ, Tyroler HA: Anger proneness predicts coronary heart disease risk: prospective analysis from the atherosclerosis risk in communities (ARIC) study. Circulation 2000;101:2034-2039.
29.
Denollet J, Brutsaert DL: Personality, disease severity, and the risk of long-term cardiac events in patients with a decreased ejection fraction after myocardial infarction. Circulation 1998;97:167-173.
30.
Deffenbacher JL, Oetting ER, Thwaites GA, Lynch RS, Baker DA, Stark RS, Thacker S, Eiswerth-Cox L: State-trait anger theory and the utility of the trait anger scale. J Couns Psychol 1996;43:131-148.
31.
Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
32.
Bogousslavsky J: William feinberg lecture 2002: emotions, mood, and behavior after stroke. Stroke 2003;34:1046-1050.
33.
Botez SA, Carrera E, Maeder P, Bogousslavsky J: Aggressive behavior and posterior cerebral artery stroke. Arch Neurol 2007;64:1029-1033.
34.
Choi-Kwon S, Han S, Kwon S, Kang D, Choi J, Kim J: Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness a double-blind, placebo-controlled study. Stroke 2006;37:156-161.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.